Compare TWI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWI | RZLT |
|---|---|---|
| Founded | 1890 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.1M | 471.0M |
| IPO Year | 1997 | 2011 |
| Metric | TWI | RZLT |
|---|---|---|
| Price | $6.77 | $3.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $12.00 | $9.80 |
| AVG Volume (30 Days) | 535.1K | ★ 1.7M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.95 | N/A |
| Revenue Next Year | $4.18 | $2,214.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.37 | $1.07 |
| 52 Week High | $11.70 | $11.46 |
| Indicator | TWI | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 42.25 |
| Support Level | $6.46 | $3.69 |
| Resistance Level | $7.43 | $4.09 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 37.90 | 30.84 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. It designs and manufactures products for OEMs and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. The company operates through three segments, namely Agricultural, Earthmoving/Construction, and Consumer. It derives the majority of revenue from the Agricultural segment which manufactures various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment. Geographically, the company generates the maximum revenue from North America, followed by Europe / CIS, Latin America, and Asia and other regions.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.